Daré does a reverse merger with an ailing Cerulean; Pulmocide raises $30.4M for RSV therapy
→ Daré Bioscience is the latest biotech to pull off a reverse merger. The company is taking over Cerulean, leaving it with a majority …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
